Senior Editor, OncLive®
Jason Harris has worked in journalism for more than 20 years, including stints at daily newspapers and niche publications for oncology and cardiology. He is a senior editor for OncologyLive® and managing editor for Oncology Fellows and the annual Giants of Cancer Care® album. He also contributes to the OncLive On Air and OncFellows podcasts. Email: jharris@onclive.com
Daily Poziotinib Shows Promise in Untreated HER2 Exon 20–Mutant NSCLC
September 18th 2021Poziotinib, administered once daily at 16 mg, induced a median tumor reduction of 35% in patients with treatment-naïve non–small cell lung cancer harboring HER2 exon 20 mutations, according to findings from cohort 4 of the ongoing phase 2 ZENITH20 trial.
Read More
Sintilimab Improves OS in Advanced ESCC, Gastric/GEJ Cancer
September 17th 2021Findings from a pair of studies presented at the 2021 European Society for Medical Oncology Annual Meeting showed that adding sintilimab to chemotherapy significantly improved overall survival compared with chemotherapy alone in patients with unresectable, locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma and those with unresectable, locally advanced, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma.
Read More
MRgFUS Improved Sexual Function, Urinary Continence in Men with Intermediate-Risk Prostate Cancer
September 13th 2021Magnetic resonance-guided focused ultrasound focal therapy delivered to the index lesion produced better outcomes for men with intermediate-risk prostate cancer compared with radical prostatectomy or radiation therapy.
Read More
TAR-200/Cetrelimab Under Investigation in Muscle-Invasive Bladder Cancer
September 11th 2021TAR-200 plus cetrelimab may offer a superior treatment option for patients with muscle-invasive bladder cancer, and to answer this questions, investigators have initiated the randomized, phase 3 SunRISe-2 trial.
Read More
Controlling Infections Could Be Key to Improving Survival in CLL
September 9th 2021Patients with chronic lymphocytic leukemia are at an increased risk for infection whether they are in the premalignant state of monoclonal B lymphocytosis, during active surveillance for those are treatment naïve, or are on active treatment.
Read More
TDM-1/Osimertinib Combo Has Limited Efficacy for Resistant EGFR+ NSCLC
September 8th 2021The combination of ado-trastuzumab emtansine and osimertinib demonstrated minimal antitumor effects on patients with EGFR-mutated non–small cell lung cancer, according to interim data of the phase 2 TRAEMOS trial.
Read More
SIRT With Y90 Plus Chemotherapy Extends Survival for Intrahepatic Cholangiocarcinoma
September 4th 2021The addition of selective internal radiation therapy with Y90 resin microspheres to gemcitabine/cisplatin resulted in a median overall survival of 21.6 months for patients with inoperable intrahepatic cholangiocarcinoma, according to prospective phase 2 data.
Read More
NICE Recommends Abemaciclib for HR+/HER2– Advanced Breast Cancer
August 12th 2021The United Kingdom’s National Institute for Health and Care Excellence has issued draft guidance supporting the use of abemaciclib in the treatment of adult patients with metastatic hormone receptor–positive/HER2-negative breast cancer.
Read More
Cancer Organizations Call for Mandated COVID-19 Vaccines for Health Care Workers
July 26th 2021More than 50 health care professional organizations, including the American Society of Hematology, the American Society of Clinical Oncology, the American Society for Radiation Oncology, the Society for Gynecologic Oncology, and the American Medical Association issued a joint statement Monday calling for all health care employers to require COVID-19 vaccinations for all their employees.
Read More
Emerging Allogeneic CAR T Candidates Usher in a New Era
July 22nd 2021Dose-dependent engraftment of the investigative CAR T-cell therapy CYAD-211 was demonstrated in the first patient with relapsed/refractory multiple myeloma to receive this dose in the phase 1 IMMUNICY-1 trial, and no graft-versus-host disease has been reported to date.
Read More
ODAC Postpones Decision on Retifanlimab in Advanced Anal Cancer
June 24th 2021In a 13 to 4 vote, the FDA’s Oncologic Drugs Advisory Committee chose to hold off on a decision regarding accelerated approval for retifanlimab for the treatment of patients with locally advanced or metastatic squamous carcinoma of the anal canal who have progressed on or are intolerant of platinum-based chemotherapy.
Read More
Immunotherapy Is on the Rise in Glioblastoma Treatment
June 23rd 2021The University of Texas MD Anderson Cancer Center is pursuing several novel approaches, including viro-immunotherapy and genetically engineered natural killer cells to treat patients with glioblastoma, while also conducting tumor analysis to better comprehend the disease.
Read More
The fixed-dose combination of the BCL-2 inhibitor venetoclax and the humanized anti-CD20 monoclonal antibody obinutuzumab continued to confer a progression-free survival advantage over chlorambucil plus obinutuzumab for patients with previously untreated chronic lymphocytic leukemia.
Read More
Cilta-Cel Demonstrates Durable Responses at 18 Months in Relapsed/Refractory Multiple Myeloma
June 8th 2021Ciltacabtagene autoleucel, an investigational BCMA-directed CAR-T therapy, sustained efficacy and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.
Read More
Palbociclib/Fulvestrant Combo Maintains OS Benefit in HR+ Breast Cancer
June 5th 2021At a median follow-up of 73.3 months, investigators in the PALOMA-3 trial have concluded that palbociclib plus fulvestrant maintains a clinically meaningful improvement in overall survival compared with placebo plus fulvestrant for patients with HR-positive, HER2-negative advanced breast cancer.
Read More
Higher Dose of Ripretinib Improves Outcomes in Heavily Pretreated Advanced GIST
June 4th 2021Intra-patient dose escalation of ripretinib to 150 mg twice a day following disease progression extended progression-free survival for patients with advanced gastrointestinal stromal tumor after receiving fourth-line therapy.
Read More